Background: Hypovitaminosis D can have a negative impact in patients (pts) with cancer, whilst vitamin D has a demonstrated role in T-cell-mediated immune activation. We hypothesized that systematic vitamin D repletion could impact clinical outcomes in pts with cancer receiving immune-checkpoint inhibitors (ICIs). Methods: We planned a prospective observational study (PROVIDENCE) to investigate serum vitamin D levels in pts with advanced cancer receiving ICIs (cohort 1 at treatment initiation, cohort 2 during treatment) and the impact of systematic repletion in the case of hypovitaminosis on survival and toxicity outcomes. In an exploratory analysis, we compared clinical outcomes of cohort 1 with a control cohort of pts followed at the participating centers who did not receive systematic vitamin D repletion. Results: Overall, 164 pts were prospectively recruited. In cohort 1, consisting of 101 pts with 94.1% hypovitaminosis (⩽30 ng/ml) at baseline, adequate repletion with cholecalciferol was obtained in 70.1% at the three months re- assessment. Cohort 2 consisted of 63 pts assessed for vitamin D at a median time of 3.7 months since immunotherapy initiation, with no pts having adequate levels (>30 ng/ml). Even in cohort 2, systematic supplementation led to adequate levels in 77.8% of pts at the three months re-assessment. Compared to a retrospective control group of 238 pts without systematic vitamin D repletion, PROVIDENCE cohort 1 showed longer OS and time to treatment failure (TTF), p=0.013 and p=0.017. The IPTW-fitted multivariable Cox regression confirmed the significantly decreased risk of death (HR 0.55, 95%CI: 0.34-0.90) and treatment discontinuation (HR 0.61, 95%CI: 0.40-0.91) for pts from PROVIDENCE cohort 1 in comparison to the control cohort. In the context of longer treatment exposure, the cumulative incidence of any grade irAEs was higher in the PROVIDENCE cohort 1 compared to the control cohort. Nevertheless, pts from cohort 1 experienced a significantly decreased risk of all grade thyroid irAEs than the control cohort (OR 0.16, 95%CI: 0.03-0.85). Conclusions: The PROVIDENCE study suggests the potential positive impact of early systematic vitamin D supplementation on outcome of pts with advanced cancer receiving ICIs and support adequate repletion as a possible prophylaxis for thyroid irAEs.

Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study / Giudice, G. C.; Cortellini, A.; Leonetti, A.; Parisi, A.; Tiseo, M.; Bordi, P.; Michiara, M.; Bui, S.; Cosenza, A.; Ferri, L.; Testi, I.; Vincenzi, B.; Santo, V.; Ricozzi, V.; Sgargi, P.; Zustovich, F.; Stucci, L. S.; Santini, D.; Buti, S.; Bersanelli, M.. - In: TUMORI. - ISSN 0300-8916. - 109:2_suppl(2023), pp. R13.247-R13.247. [10.1177/03008916231203496]

Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study.

Giudice G. C.
Investigation
;
Leonetti A.
Investigation
;
Tiseo M.
Investigation
;
Testi I.
Investigation
;
Buti S.
Supervision
;
2023-01-01

Abstract

Background: Hypovitaminosis D can have a negative impact in patients (pts) with cancer, whilst vitamin D has a demonstrated role in T-cell-mediated immune activation. We hypothesized that systematic vitamin D repletion could impact clinical outcomes in pts with cancer receiving immune-checkpoint inhibitors (ICIs). Methods: We planned a prospective observational study (PROVIDENCE) to investigate serum vitamin D levels in pts with advanced cancer receiving ICIs (cohort 1 at treatment initiation, cohort 2 during treatment) and the impact of systematic repletion in the case of hypovitaminosis on survival and toxicity outcomes. In an exploratory analysis, we compared clinical outcomes of cohort 1 with a control cohort of pts followed at the participating centers who did not receive systematic vitamin D repletion. Results: Overall, 164 pts were prospectively recruited. In cohort 1, consisting of 101 pts with 94.1% hypovitaminosis (⩽30 ng/ml) at baseline, adequate repletion with cholecalciferol was obtained in 70.1% at the three months re- assessment. Cohort 2 consisted of 63 pts assessed for vitamin D at a median time of 3.7 months since immunotherapy initiation, with no pts having adequate levels (>30 ng/ml). Even in cohort 2, systematic supplementation led to adequate levels in 77.8% of pts at the three months re-assessment. Compared to a retrospective control group of 238 pts without systematic vitamin D repletion, PROVIDENCE cohort 1 showed longer OS and time to treatment failure (TTF), p=0.013 and p=0.017. The IPTW-fitted multivariable Cox regression confirmed the significantly decreased risk of death (HR 0.55, 95%CI: 0.34-0.90) and treatment discontinuation (HR 0.61, 95%CI: 0.40-0.91) for pts from PROVIDENCE cohort 1 in comparison to the control cohort. In the context of longer treatment exposure, the cumulative incidence of any grade irAEs was higher in the PROVIDENCE cohort 1 compared to the control cohort. Nevertheless, pts from cohort 1 experienced a significantly decreased risk of all grade thyroid irAEs than the control cohort (OR 0.16, 95%CI: 0.03-0.85). Conclusions: The PROVIDENCE study suggests the potential positive impact of early systematic vitamin D supplementation on outcome of pts with advanced cancer receiving ICIs and support adequate repletion as a possible prophylaxis for thyroid irAEs.
2023
Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study / Giudice, G. C.; Cortellini, A.; Leonetti, A.; Parisi, A.; Tiseo, M.; Bordi, P.; Michiara, M.; Bui, S.; Cosenza, A.; Ferri, L.; Testi, I.; Vincenzi, B.; Santo, V.; Ricozzi, V.; Sgargi, P.; Zustovich, F.; Stucci, L. S.; Santini, D.; Buti, S.; Bersanelli, M.. - In: TUMORI. - ISSN 0300-8916. - 109:2_suppl(2023), pp. R13.247-R13.247. [10.1177/03008916231203496]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2992857
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact